Our study underscores that the development of a cisplatin derivative conjugated with an anti-PD-L1 Fab would be the ideal option for HNSCC treatment, as both combination therapy and a low-toxicity chemotherapeutic formulation would be included in a single therapeutic agent. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.